Skip to main content

Table 2 Side effects of BCNU-based chemotherapy classified according to CTCAE v.2.0

From: Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients

Side Effects (%)

CTCAE I

CTCAE II

CTCAE III

CTCAE IV

Patients with side effects

51 (31)

23 (14)

8 (5)

7 (4)

Leukopenia

38 (22,8)

17 (10,2)

2 (1,2)

1 (0,6)

Thrombocytopenia

35 (21)

5 (3)

5 (3)

1 (0,6)

Anemia

16 (9,6)

-

1 (0,6)

-

Nausea/Vomitus

3 (1,8)

2 (1,2)

-

-

Fatigue

1 (0,6)

-

-

-

Obstipation/Diarrhea

2 (1,2)

-

-

-

Pulmonary Fibrosis

-

-

-

1 (0,6)

Thromboembolism

-

-

1 (0,6)

1 (0,6)

Hemorrhage

-

-

-

1 (0,6)

Injection Site Reaction

1 (0,6)

2 (1,2)

1 (0,6)

-

Othersa

4 (2,4)

2 (1,2)

2 (1,2)

1 (0,6)

  1. aSide effects classified as “others” were found in timely but not necessarily causal relation to BCNU administration and consisted of weight loss/loss of appetite CTCAE I (1.2 %), arterial hypotension CTCAE I (0.6 %), neuropathic pain CTCAE I (0.6 %), newly observed cranial nerve deficit CTCAE II (0.6 %), photophobia CTCAE II (0.6 %) and hallucinations CTCAE III (0.6 %), anaphylaxis CTCAE III (0.6 %) and isolated elevation of liver transaminases CTCAE IV (0.6 %)